Navigation Links
A potential new target for treatment of hormone refractory prostate cancer
Date:4/6/2009

A new study identifies a protein that modifies the androgen receptor (AR) and influences its ability to regulate target genes linked with the progression of prostate cancer. The research, published by Cell Press in the April 7th issue of the journal Cancer Cell, may also drive creation of new strategies for the treatment of advanced prostate cancer that no longer responds to traditional anti-hormone therapies.

The AR is an important mediator for the development and progression of prostate cancer, including the progression to the aggressive and often lethal androgen-independent form of the disease. "Androgen ablation therapy is the most common treatment for advanced prostate cancer," offers senior study author, Dr. Yun Qiu from the University of Maryland School of Medicine. "However, many patients inevitably develop deadly recurrent cancers, which no longer respond to androgen blockade and are resistant to current therapy."

To better understand mechanisms associated with advanced prostate cancer, Dr. Qiu and colleagues performed a screen designed to search for proteins that interact with the AR in hormone-refractory prostate cancer cells. The researchers identified RNF6 as an AR associated protein and demonstrated that RNF6 induced ubiquitination of the AR and promoted AR transcriptional activity. Ubiquitination is a common protein modification that mediates a diverse range of cellular activities. One of the best known functions of ubiquitination is to promote protein degradation. However, ubiquitination of AR by RNF6 appeared to have a stabilizing effect on AR protein.

Importantly, inhibition of RNF6 or interference with ubiquitination of AR altered expression of a specific group of AR target genes and abrogated recruitment of AR and its required coactivators to androgen-responsive regulatory regions in these genes. The researchers went on to show that expression of RNF6 was increased in human prostate cancer tissues that do not respond to androgen ablation and is required for prostate tumor growth under androgen depleted conditions.

Taken together, the findings implicate RNF6 as an important regulator of AR transcriptional activity. "Our work suggests that ubiquitination of AR, and possibly other transcription factors, may function as the scaffold for cofactor recruitment to modulate transcriptional activity and specificity," concludes Dr. Qiu. "Targeting components of the ubiquitination machinery, such as RNF6, may potentially be effective in treatment of advanced prostate cancer."


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. UCLA study identifies designer estrogen as potential MS drug
3. Office-Based Medical Treatment and Internet Resources Are Potential Solution to Rising Painkiller Misuse Among Teens, Young Adults
4. Common abdominal pain may be due to a potentially treatable newly recognized inflammatory reaction
5. Potential new approach to treat cognitive impairments in schizophrenia
6. Nosespray vaccine using aloe vera has exciting potential, researcher says
7. Network approach identifies potential breast cancer susceptibility gene
8. Liver fibrosis will be treated by a potential target
9. Researchers study potential health benefits of natural chemicals in muscadine grape seeds
10. Jefferson researchers find stem cells in degenerating spinal discs, potential for repair
11. China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... PARIS and NEW YORK , Sept. 12, ... ethical performance ratings for global supply chains, has published the first annual ... the CSR performance of more than 20,400 companies evaluated by EcoVadis, based ... years 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/12/2017)... SAN FRANCISCO , Sept. 12, 2017 /PRNewswire/ ... Lifecycle Management Solutions (VLMS), is pleased to announce ... as a member of its Board of Directors ... 2017. ValGenesis VLMS enables life science companies to ... eliminate the use of paper in this process. ...
(Date:9/9/2017)... Dealmed Medical Supplies, New York ... supplies, drugs, vaccines, and specialty medical products and services, ... to acquire Vantage Medical Supplies, a major distributor of ... New York . ... medical practices, will operate under the Dealmed name as ...
Breaking Medicine Technology: